Infliximab Exerts No Direct Hepatotoxic Effect on HepG2 Cells In Vitro

被引:12
作者
de Vries, Hilbert S. [1 ]
de Heij, Tineke [1 ]
Roelofs, Henie M. J. [1 ]
te Morsche, Rene H. M. [1 ]
Peters, Wilbert H. M. [1 ]
de Jong, Dirk J. [1 ]
机构
[1] Radboud Univ Nijmegen, Med Ctr, Dept Gastroenterol & Hepatol, NL-6500 HB Nijmegen, Netherlands
关键词
Inflammatory bowel disease; Hepatotoxicity; HepG2; cells; Infliximab; Methotrexate; Azathioprine; 6-mercaptopurine; 6-thioguanine; INFLAMMATORY-BOWEL-DISEASE; HUMAN HEPATOCYTES; RHEUMATOID-ARTHRITIS; LIVER-REGENERATION; IMMUNE-COMPLEXES; AZATHIOPRINE; 6-MERCAPTOPURINE; BIOAVAILABILITY; ANTIBODIES; HEPATITIS;
D O I
10.1007/s10620-012-2159-7
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Infliximab-induced hepatotoxicity is reported in several case studies involving patients with inflammatory bowel disease (IBD) and a direct hepatotoxic effect has been proposed. The aim of this study was to determine the direct in vitro toxicity of infliximab. As a proof of principle the in vitro toxicity of thiopurines and methotrexate was also determined. Cell survival curves and the half maximal inhibitory concentrations (IC50) were obtained after 24, 48 and 72 h of incubation in HepG2 cells with the IBD drugs azathioprine, 6-mercaptopurine, 6-thioguanine, methotrexate or infliximab by using the WST-1 cytotoxicity assay. No in vitro hepatotoxicity in HepG2 cells was seen with infliximab, while concentration-dependent cytotoxicity was observed when HepG2 cells were incubated with increasing concentrations of azathioprine, 6-mercaptopurine and 6-thioguanine. Infliximab alone or given in combination with azathioprine showed no direct hepatotoxic effect in vitro, indicating that the postulated direct hepatotoxicity of infliximab is unlikely.
引用
收藏
页码:1604 / 1608
页数:5
相关论文
共 27 条
[1]   Hepatotoxicity related to antirheumatic drugs [J].
Aithal, Guruprasad P. .
NATURE REVIEWS RHEUMATOLOGY, 2011, 7 (03) :139-150
[2]   ANTIBODIES TO TUMOR-NECROSIS-FACTOR-ALPHA INHIBIT LIVER-REGENERATION AFTER PARTIAL-HEPATECTOMY [J].
AKERMAN, P ;
COTE, P ;
YANG, SQ ;
MCCLAIN, C ;
NELSON, S ;
BAGBY, GJ ;
DIEHL, AM .
AMERICAN JOURNAL OF PHYSIOLOGY, 1992, 263 (04) :G579-G585
[3]   Anti-Tumor Necrosis Factor α Treatment Promotes Apoptosis and Prevents Liver Regeneration in a Transgenic Mouse Model of Chronic Hepatitis C [J].
Brenndorfer, Erwin Daniel ;
Weiland, Malin ;
Frelin, Lars ;
Derk, Emma ;
Ahlen, Gustaf ;
Jiao, Jian ;
Bode, Johannes Georg ;
Sallberg, Matti .
HEPATOLOGY, 2010, 52 (05) :1553-1563
[4]  
Bruccoleri A, 1997, HEPATOLOGY, V25, P133, DOI 10.1002/hep.510250125
[5]  
CHAN GLC, 1987, PHARMACOTHERAPY, V7, P165
[6]   Accumulation of plasma nucleosomes upon treatment with anti-tumour necrosis factor-α antibodies [J].
D'Auria, F ;
Rovere-Querini, P ;
Giazzon, M ;
Ajello, P ;
Baldissera, E ;
Manfredi, AA ;
Sabbadini, MG .
JOURNAL OF INTERNAL MEDICINE, 2004, 255 (03) :409-418
[7]   High variation of tioguanine absorption in patients with chronic active Crohn's disease [J].
Deibert, P ;
Dilger, K ;
Fischer, C ;
Hofmann, U ;
Nauck, S ;
Stoelben, S ;
Kreisel, W .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 18 (02) :183-189
[8]  
DING TL, 1979, DRUG METAB DISPOS, V7, P373
[9]   Systemic and intestinal pharmacokinetics of methotrexate in patients with inflammatory bowel disease [J].
Egan, LJ ;
Sandborn, WJ ;
Mays, DC ;
Tremaine, WJ ;
Fauq, AH ;
Lipsky, JJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (01) :29-39
[10]  
Federal Drug Administration, 2009, REMICADE INFL 4 INJ